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Objective: To determine the anti-breast cancer activities and the safety oral consumption
of Dillenia suffruticosa root aqueous extract (DRAE) in BALB/c mice.
Methods: In the anti-breast cancer study, female BALB/c mice were divided into ﬁve
groups (n = 12), which were (1) positive control (with breast cancer, untreated), (2)
negative control (without breast cancer, untreated) and other three groups of mice with
breast cancer treated with 1000, 500 and 250 mg/kg of DRAE, respectively, by oral
gavage for 28 days. All mice except from the negative control group were injected into
the mammary fat pad with 4T1 cells (1 × 105 4T1 cells/0.1 mL of phosphate buffer
solution). DRAE was administered orally on Day 11 after the tumor has developed.
Results: The tumor volume of the 1000 mg/kg of DRAE group reduced signiﬁcantly
compared to the positive control while treatment with 500 mg/kg of DRAE had signif-
icantly inhibited metastasis to the heart. In the acute toxicity study, treatment with up to
5000 mg/kg of DRAE was not toxic to the animals, indicating its safety when a large
amount of this plant extract was ingested. Based on the sub-acute toxicity study, treatment
of the highest dose of DRAE (1000 mg/kg) had mild liver toxicity indicated by mild focal
hemorrhage.
Conclusions: DRAE possesses anti-breast cancer properties but at the same time it
shows mild toxicity to the liver. The non observable adverse effect dose for DRAE is
500 mg/kg.1. Introduction
Breast cancer is the most common cancer in women world-
wide. It is also the principle cause of death from cancer among
women globally. The incidence of breast cancer has been on the
rise in the developing countries due to the increasing life ex-
pectancy, urbanization and adoption of western lifestyles [1].Statistics show that nearly 1.7 million people were diagnosed
with breast cancer and 522000 of reported breast cancer-
related deaths in 2012 worldwide [2]. Majority of the breast
cancer-related death is the results of uncontrollable metastasis.
Although it affects only 10%–15% of the cases, breast cancer
can spread to other parts of the body within 3 years of its initial
diagnosis, and metastasis tends to recur later, up to 10 years or
more after the detection of the primary tumor [3].
Surgery, hormone therapy, chemotherapy, radiation therapy
and selective combination of aforementioned therapies have
been the standard treatments of breast cancer. Nevertheless, they
are not completely effective in the treatment of metastatic breast
cancer [4]. Moreover, chemotherapy comes with unpleasant
adverse effects such as hair loss, nausea, vomiting, anemia,
joint pain, leukemia and heart failure [5]. Patients may developan open access article under the CC BY-NC-ND
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tumor cells resistant to anticancer drug during the course of
treatment frequently has resulted in failure to subsequent
therapy, relapse of rapid tumor growth and patient mortality [6].
Therefore, scientists have begun to search for new more
effective alternative anticancer drugs that derive from natural
products including plants. Indeed, plants have become an
important source of currently clinically available anti-cancer
drugs such as vinca alkaloids (vinblastine and vincristine)
extracted from the Catharanthus roseus [7], taxane diterpenoids
(paclitaxel and irinotecan) from Taxus brevifolia [8], and
camptothecins quinoline alkaloid derivatives (topotecan and
irinotecan) from Camptotheca acuminate [9]. It has been
reported that more than 50% of all modern drugs in clinical
use are of natural products, many of which have been
recognized to have the ability to induce apoptosis [9].
Dillenia suffruticosa Grifﬁth ex Hook. F. and Thomson
(Martelli Dilleniaceae) (D. suffruticosa) is locally known as
“Simpoh Air” by the Malays and “Shrubby Simpoh” by the
people of Hawaii [10]. It is an evergreen tree that has red colored
fruits and attractive yellow colored ﬂowers. In East Malaysia,
the Rungus ethnic had been using D. suffruticosa to treat
cancerous growth [11]. This plant has been traditionally used in
the state of Perak, Peninsular Malaysia, as traditional remedies
to treat microbial and fungal infections [12,13]. It is reported
that D. suffruticosa has been long used by the indigenous and
the local people of Sabah to treat headache and has wound
healing properties [14,15].
Our previous studies showed that the root extract of
D. suffruticosa exhibited stronger cytotoxic activities against
human cancer cell lines including HeLa, MCF-7, MDA-MB-
231, A549 and HT-29, as compared to other parts of the plant
[16]. The ethyl acetate extract of D. suffruticosa root exhibited
cytotoxic effect by induction of oxidative stress in MCF-7 cell
line [17]. In addition, the root dichloromethane extract of
D. suffruticosa induced apoptosis and cell cycle arrest via up-
regulation of NF-kB and JNK1, and down-regulation of AKT1
and ERK1 [18].
Although D. suffruticosa is traditionally used for treatment of
cancerous growth, no information of its anti-breast properties
and safety is available. This study determined the anti-breast
cancer activities and the safety for oral consumption of
D. suffruticosa root aqueous extract (DRAE) in BALB/c mice.
2. Materials and methods
2.1. Plant material
The ﬁne powder of root of D. suffruticosa was supplied by
Primer Herber Sdn. Bhd., Malaysia. The plant was identiﬁed and
authenticated at the Biodiversity Unit, Institute of Bioscience,
Universiti Putra Malaysia (Voucher specimen number SK 1937/
11).
2.2. Preparation of DRAE
Brieﬂy, 500 g of D. suffruticosa dry root powder was soaked
in distilled water (1:4, w/v) and boiled for 5 min. After cooling
down, the mixture was ﬁltered through Whatman No. 1 ﬁlter
paper. The residue was re-extracted twice. The ﬁltrates were
pooled and lyophilized by freeze-drying (VirTisbenchtop K,Bieleveld, Germany). The yield of extraction was approximately
5% (w/w). The lyophilized powder was stored at −20 C for
further use. The percentage of yield was calculated by using the
formula as follows [19]:
Yield ð%Þ = Weight of crude extract
Weight of dried plant materials
× 100
2.3. Cell line
The 4T1 mouse mammary carcinoma cells (4T1 ATCC®
CatalogNo. CRL-2539™) were purchased from the American
Type and Culture Collection (Manassas, VA, USA). The cells
were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin, and main-
tained in a humidiﬁed incubator at 37 C in atmosphere of 5%
CO2.
2.4. Experimental animal
The protocol of the study was approved by the Animal Care
and Use Committee, Faculty of Medicine and Health Sciences,
UPM (Approval No. UPM/FPSK/PADS/BR-UUH/00505). Fe-
male BALB/c mice with 20–30 g in weight at the age of 6–8
weeks were used in this study. They were housed individually in
cages under standard laboratory conditions with a period of 12/
12-h light/dark cycle, at 20–24 C with 40%–50% relative hu-
midity. The animals were acclimatized for one week before the
actual experiment. The mice were fed with a standard chow
pellet (Specialty Food, Australia) and allowed to drink water ad
libitum.
2.5. Experimental design
2.5.1. In vivo anti-breast tumor study
Sixty female BALB/c mice were divided into 5 groups
(n = 12), which were (1) positive control (with breast cancer,
untreated), (2) negative control (without breast cancer, un-
treated) and other three groups of mice with breast cancer treated
with 1000 mg/kg, 500 mg/kg and 250 mg/kg of DRAE. All
mice except from the negative control group were injected into
the mammary fat pad with 4T1 cells (1 × 105 4T1 cells/0.1 mL
of PBS). On Day 11, DRAE was administered orally to the
animals via gavage for 28 days, following injection of 4T1 cells.
Mice were weighed three times a week. The tumor volume was
measured twice weekly by using a vernier caliper. The following
formula was used to determine the volume of the tumors [20]:
Volume of the tumors = Length × width2 × 0.52
Mice that were moribund were sacriﬁced and the date of
sacriﬁce was recorded for calculating the survival time. The
major organs (kidneys, liver, heart, lungs and spleen) were
harvested, weighed and observed grossly. The presence of
metastasis was recorded [20]. For each mouse, the organ weight
to body weight percentage ratio was calculated.
2.5.2. Acute toxicity study
Twenty mice were randomly assigned into ﬁve groups
(n = 4), which were the control and four treatment groups of
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Figure 1. Change in the body weight of 4T1 tumor-bearing mice treated
with different dose of DRAE.
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Figure 2. Organ to body weight ratio of 4T1 tumor-bearing mice treated
with different dose of DRAE.
a–c: Mean with different superscripts differs signiﬁcantly (P < 0.05).
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DRAE). Prior to the acute toxicity study, the dose of DRAE was
determined through a preliminary test. Control group received
distilled water only. For the treatment groups, the lyophilized
DRAE was dissolved in distilled water and orally administered
by gavage only on the ﬁrst day. The animals were observed in
the ﬁrst 4 h after dosing and then daily for 14 days for general
appearance, behaviour, toxicity symptoms and mortality. The
body weight was measured daily by using a table top electronic
balance (A&D SK-5001WP, Japan).
2.5.3. Sub-acute toxicity study
The mice were randomly assigned into four groups (n = 8),
which were the control and three treatment groups of escalating
dose (250, 500 and 1000 mg/kg of DRAE). Control group
received distilled water only. For the treatment groups, the
lyophilized DRAE was dissolved in distilled water and orally
administered by gavage daily for 28 days. The animals were
observed twice daily (before and after dosing) for general
physical conditions such as general appearance, behaviour,
toxicity symptoms and mortality in 28 days. The body weight
was measured every 3 days (Days 1, 4, 7, 10, 13, 16, 19, 22, 25
and 28).
2.5.4. Biochemical analysis
Blood collection was carried out on Day 29 in the sub-acute
toxicity study. Prior to blood collection, the mice were anes-
thetized with diethyl ether. The blood samples (1 mL) were
collected by cardiac puncture by using a 26 G × 1/2 needle”
(Terumo®, Belgium, Europe) and centrifuged at 14000 r/min for
10 min to separate the serum. Blood analysis was carried out by
using a chemistry analyzer (Selectra XL, Dieren, Netherlands).
For hepatic function, level of serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gamma glutamyl-
transpeptidase (GGT) and alkaline phosphatise (ALP) were
evaluated. For renal function, level of blood urea nitrogen and
serum creatinine was determined.
2.5.5. Histological examination
Following blood sampling, the mice were sacriﬁced by suf-
focating with diethyl ether in a glass desiccator. Tumors and
organs including heart, lungs, kidneys, spleen and liver were
harvested and ﬁxed in 10% formalin. After ﬁxation for at least
24 h, the tissues were processed for 16 h by an automated tissue
processer (Leica ASP6025, Leica Microsystems, Wetzlar, Ger-
many). Processed tissues were then embedded in parafﬁn. Four
micrometres thick sections were cut from the parafﬁn block and
stained with hematoxylin and eosin (H&E). Each slide was
examined under a light microscope with assistance of a
pathologist. At least 10 ﬁelds from each slide of each group were
examined to evaluate the histological changes.
For anti-breast cancer study, the scoring was done based on
the presence of metastatic cells in the organs. Slides were
screened for any metastatic cell and any organ that had one
metastatic cell and then recorded as “with metastasis”. For
toxicity studies, the scoring system for histological changes of
liver and kidney was according to Jihen et al. on degree of
chromatin condensation, nucleus fragmentation, necrosis of
hepatocytes, light cytoplasm and sinusoidal widening in liver
while degree of dilation in the glomeruli and tubular necrosis in
kidney [21].2.6. Statistical analysis
Data were analyzed with One-way ANOVA, Dunnett's,
Mann–Whitney, and Duncan's multiple range test by using SPSS
version 20.0. All the data were expressed as mean ± SD.
Probability of P < 0.05 was considered signiﬁcant.
3. Results
3.1. Anti-breast cancer study
3.1.1. Body weight
Figure 1 illustrates that the weight between all DRAE-treated
groups and controls were not signiﬁcantly different (P > 0.05).
3.1.2. Organ to body weight ratio
The organ to body weight ratios of DRAE-treated groups and
controls are illustrated in Figure 2. The treatment groups (250,500 and 1000 mg/kg of DRAE) and the positive control showed
signiﬁcant increase of lung, spleen and liver to body weight ratio
(P < 0.05) compared to the negative control. The spleen to body
weight ratio of the 1000 mg/kg DRAE-treated group decreased
signiﬁcantly (P < 0.05) compared to the positive control.
3.1.3. Tumor volume
Figure 3 shows the volume of tumors from DRAE-treated
groups and positive control. There was no signiﬁcant differ-
ence in the tumor volume between the treatment groups and the
positive control. On Day 30, the tumor volume of the 1000 mg/
kg DRAE group reduced signiﬁcantly compared to the positive
control (P < 0.05).
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Figure 3. Volume of tumors of 4T1 tumor-bearing mice treated with
different dose of DRAE.
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The percentage of organs that is metastasis-free is shown in
Table 1. Treatment with 500 mg/kg of DRAE has signiﬁcantly
inhibited metastasis to the heart (P < 0.05).Negative control
Figure 4. Representative sections of lungs sections from mice untreated
and treated with different dose of DRAE following H&E staining as
observed under a light microscope (200×).
Metastatic cells were marked by arrows.
gk/gm005gk/gm0001
lortnocevitisoPgk/gm052
Negative control
Figure 5. Representative sections of heart from mice untreated and treated
with different dose of DRAE following H&E staining as observed under a
light microscope (200×).
Metastatic cells were marked by arrows.
Table 1
Percentage of organs free of metastasis following treatment with DRAE.
Group Metastasis-free organ (%)
Lung Liver Heart Spleen
1000 mg/kg 0 60 60 100
500 mg/kg 0 60 80* 100
250 mg/kg 0 80 40 100
Positive control 0 100 0 100
*: Signiﬁcantly (P < 0.05) differs from the positive control group
according to Mann–Whitney test.3.1.5. Histopathological changes
Figure 4 shows the representative of H&E staining sections
of lungs of mice treated with different doses of DRAE and the
control groups as observed under a light microscope. All
DRAE-treated and positive control mice exhibited inﬁltration
of neoplastic cells in the lungs and structural destruction of the
pulmonary alveoli. There was a reduction of alveolar sacs,
which were spaces at the termination of the alveolar ducts that
were surrounded by alveoli, due to inﬁltration of the
neoplastic cells. The neoplastic cells were poorly differenti-
ated (bear minimal resemblance to the cell from which they
arose) and characterized by the presence of large hyper-
chromatic nuclei and small amount of cytoplasm. The meta-
static cells in lungs appeared in clusters or clumps and were
marked by arrows.
Figure 5 shows the representative of H&E staining sections
of hearts of mice treated with different doses of DRAE and the
control groups as observed under a light microscope. The
DRAE-treated and positive control mice exhibited inﬁltration of
neoplastic cells in the heart. The neoplastic cells were poorly
differentiated (bear minimal resemblance to the cell from which
they arose) and characterized by the presence of large hyper-
chromatic nuclei and small amount of cytoplasm. The metastatic
cells in lungs appeared in clusters or clumps and were marked by
arrows.
Figure 6 shows a representative of H&E staining section of a
primary tumor from the positive control. The neoplastic cells
were poorly differentiated as they bore minimal resemblance to
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Large hyperchromatic nuclei and relatively small amount of
cytoplasm were noted. The primary tumor showed the presence
of necrosis inﬁltration by leucocytes. The areas of necrosis were
marked by arrows.Magnification 200× Magnification 400×
Figure 6. A section from a primary tumor illustrating area of necrosis
(arrows) following H&E staining as observed under a light microscope. The
neoplastic cells were poorly differentiated and characterized by small
amount of cytoplasm.
1 000 mg/kg 500 mg/kg
250 mg/kg Positive controlThe spleens harvested from the positive control showed signs
of splenomegaly, which were changes in splenic architecture and
increased number of immature splenic granulocytes (Figure 7a).
An expansion of the granulocyte rich red pulp (marked by R)
with reduction in white pulp area (marked by W) in the spleen of
the positive control as compared to the negative control is shown
in Figure 7b and Figure 7c. White and red pulps were named
based on the color of fresh section. The white pulp consisted of
lymphatic tissue, mostly lymphocytes and appeared basophilic
because of the dense heterochromatin in the nuclei of the
numerous lymphocytes. The red pulp had a red appearance in
fresh state as well as in histologic sections because it contained
large number of red blood cells. Spleens of positive control
showed prominent megakaryoblast (arrows) in the splenic red
pulp (Figure 7d).a b
dc
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R
Figure 7. Representative sections of spleen from mice untreated and
treated with different dose of DRAE following H&E staining as observed
under a light microscope (200×).
a: Difference in spleen size between negative control (A) and tumor bearing
mouse (B); b: H&E staining section of a spleen of a tumor bearing mouse
(200×); c: H&E staining section of a mouse from the negative control group
(200×); d: H&E staining section of a spleen of a tumor bearing mouse
(400×).Figure 8 shows the representative of H&E staining sections
of livers of mice treated with different doses of DRAE and the
control groups as observed under a light microscope. The
DRAE-treated groups and positive control showed inﬁltration of
neoplastic cells in the liver. The neoplastic cells were poorly
differentiated (bear minimal resemblance to the cell from which
they arose) and characterized by the presence of large hyper-
chromatic nuclei and small amount of cytoplasm. The metastatic
cells in lungs appeared in clusters or clumps and were marked by
arrows.Negative control
Figure 8. Representative sections of liver from mice untreated and treated
with different dose of DRAE following H&E staining as observed under a
light microscope (200×).
Metastatic cells are marked by arrows.3.2. Acute toxicity study
There was no treatment-related mortality observed in mice
treated at any dose level of DRAE (625, 1250, 2500 and
5000 mg/kg body weight). All the mice appeared healthy with
normal eyes, fur and skin condition during 14 days of obser-
vation period. No abnormalities such as hemorrhage, lesions,
enlargement or atrophy in organs were observed following
macroscopic post-mortem examinations of the animals. Per-
centage of body weight change in mice treated with DRAE for
14 days is illustrated in Figure 9. None of the mice experienced
signiﬁcant weight loss throughout the experimental period.
However, there was a signiﬁcant increase (P < 0.05) in body
weight of mice treated with 5000 mg/kg of DRAE after Day 10
compared to the control. Figure 10 illustrates the percentage of
organ to body weight ratio of various organs (kidneys, liver,
spleen and lungs) in BALB/c mice treated with DRAE. The
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Figure 9. Change in body weight of mice treated with different dose of
DRAE in the acute toxicity study.
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increase (P < 0.05) in the kidney weight compared to the con-
trol. There was an absence of any histological changes such as
chromatin condensation, nucleus fragmentation, light cytoplasm
and sinusoidal widening in the liver. The kidneys of mice in all
treatment groups did not show any changes in glomeruli dilation
and tubular necrosis (data not shown).1.2
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Figure 10. Organ to body weight ratio of mice treated with different dose
of DRAE in the acute toxicity study.
a–b: Mean with different superscripts differs signiﬁcantly (P < 0.05).
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Figure 12. Organ to body weight ratio of mice treated with different dose
of DRAE in the sub-acute toxicity study.
a–b: Mean with different superscripts differs signiﬁcantly (P < 0.05).
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Figure 13. Plasma level of ALP, ALT, AST, GGT, urea and creatinine in
mice treated with different dose of DRAE in the sub-acute toxicity study.3.3. Sub-acute toxicity study
3.3.1. Clinical observations and mortality
There was no treatment-related mortality of mice at any dose
level of DRAE tested (250, 500 and 1000 mg/kg body weight).
During treatment for 28 days, DRAE did not induce any toxicity
symptom in the mice even at the highest dose (1000 mg/kg). All
the mice appeared healthy with normal eyes, fur and skin con-
dition. No abnormalities such as hemorrhage, lesions, enlarge-
ment or atrophy in organs were observed following macroscopic
post-mortem examinations of the animals.
3.3.2. Body weight change and organ to body weight
ratio
Percentage of body weight change in BALB/c mice treated
with DRAE for 28 days is illustrated in Figure 11. At the
beginning of the treatment, there was a slight body weight drop
in mice of all the treated groups (250, 500 and 1000 mg/kg).
Figure 12 illustrates the percentage of organ to body weight ratio
of various organs (kidneys, liver, spleen, lungs, heart and
stomach) of mice treated with DRAE. There was no signiﬁcant
difference (P > 0.05) in the percentage of organ to body weight
ratio between all the treatment groups and the control.3.3.3. Level of liver enzymes and kidney functions
Figure 13 illustrates the plasma level of AST, ALT, GGT,
ALP, urea and creatinine in BALB/c mice treated with DRAE in
the sub-acute toxicity study. There was no signiﬁcant difference
(P > 0.05) in all the biochemical parameters between all the
treatment groups and the control.3.3.4. Histological changes
There was an absence of any histological changes such as
chromatin condensation, nucleus fragmentation, light cytoplasm
and sinusoidal widening in the liver. However, there was a focal
mononuclear cell inﬁltrations in the mice treated with 1000 mg/
kg DRAE (Figure 14). The kidneys of mice in all treatment
groups did not show any changes in glomeruli dilation and
tubular necrosis (data not shown).
BA
DC
Figure 14. The liver tissue of control and mice treated with different dose
of DRAE following H&E staining as observed under a light microscope
(400× magniﬁcation).
A: Control; B: Mice fed with 250 mg/kg DRAE; C: Mice fed with 500 mg/
kg DRAE; D: Mice fed with 1000 mg/kg DRAE showing mild focal
hemorrhage (white arrow).
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The acute toxicity study of DRAE was conducted in accor-
dance with Organization for Economic Co-operation and
Development (OECD) 420 guideline for testing of chemicals
with modiﬁcation in selection of dose level [22], while the sub-
acute toxicity study was conducted under OECD 407 guide-
line for the testing of chemicals [23]. Any moribund mouse will
be euthanized. The endpoints of the experiment are the time
when the animal experiences body weight loss of 20% in one
week, inability to eat or drink, immobility and lack of
responsiveness to manual stimulation.
The anti-breast cancer properties of DRAE were evaluated in
this study. The weight of the DRAE-treated groups and positive
control increased for the ﬁrst 5 weeks after breast cancer in-
duction and started to reduce at the end of the experiment. The
increase is probably due to the growth of the tumors. The tumors
increased in volume from Day 10 till Day 38 after breast cancer
induction. The tumor-bearing mice showed the characteristics of
cancer anorexia. Anorexia is an involuntary weight loss, tissue
wasting and poor performance, which will ultimately result in
death [24]. According to the UK Home Ofﬁce Regulation, weight
loss is expected in mice induced with breast cancer, and the mice
can lose up to 25% of their body weight after 4 weeks of breast
cancer induction [25]. From this study, even though the weight
loss of all the treated groups and controls was not signiﬁcant,
weight loss was still one of the symptoms of cancer anorexia-
cachexia syndrome. Cancer cachexia is deﬁned as a wasting
syndrome involving loss of muscle mass and fat directly caused
by tumor factors or indirectly caused by an aberrant host
response to tumor presence [26].
Liver and the spleen of the DRAE-treated and positive con-
trol mice showed signiﬁcant increase in weight compared to the
normal mice due to the extramedullary hematopoiesis (Figure 8).
The presence of tumor increased the circulating neutrophils and
other leukocytes, which caused the enlargement of the spleen
and the liver [27]. Splenomegaly has been reported in breast
tumor-induced leukemoid reaction [28–30]. Neoplasia associatedwith leukemoid reaction, although uncommon in both human
and animals, has been reported in several animals and human
cancers. Breast cancer has rarely been reported to induce
granulocytosis in humans but there are several granulocytosis-
inducing tumors described in animals [27,31]. The average
weight of spleen for 1000 mg/kg group showed a signiﬁcant
reduction compared to the positive control. This suggests that
at 1000 mg/kg of DRAE, breast cancer-induced extra-
medullary hematopoiesis in spleen can be reduced.
The volume of tumors (Figure 9) between the DRAE-treated
groups and the control group was insigniﬁcantly different
throughout the study, except for treatment at 1000 mg/kg DRAE
on Day 30, where the tumor volume did not increase compared
to Day 26. Nevertheless, it was a transient growth inhibition
whereby the tumor volume continued to increase after Day 30.
The mechanism of the transient growth inhibition remains un-
clear. DRAE alone is probably not that effective in treating
metastatic breast cancer. In the adjuvant setting, combination
chemotherapy is used routinely due to widespread evidence that
polychemotherapy offers a survival advantage compared with
single-agent therapy [32]. Studies showed that combination and
sequential therapy were effective in treating metastatic breast
cancer. Drug combinations, such as paclitaxel/trastuzumab or
capecitabine/docetaxel, showed survival advantages over
single-agent therapy [33]. Despite not showing any signiﬁcant
reduction in tumor volume as compared to the control group,
the treatment groups however showed a reducing trend in
tumor volume. The size of tumors of the DRAE-treated group
was lower as compared to the positive control.
Mice treated with DRAE showed no metastatic inhibition in
the lungs. Lungs are by far the most likely organ to be affected
by metastasis [34]. The 4T1 cells formed distinct metastatic foci,
mostly in the lung. The present study also showed that
metastasis was not found in the spleen. The enlargement of
the spleens of the DRAE-treated and positive control mice
was due to extramedullary hematopoiesis. There was a signiﬁ-
cant reduction of metastasis in the heart of tumor-bearing mice
treated with 500 mg/kg DRAE as compared to the positive
control. Eighty percent of heart of mice treated with 500 mg/kg
DRAE showed no metastasis. It is speculated that DRAE at
certain dose (effective dose) has the ability to prevent the for-
mation of heart metastasis [20].
4.1. Acute toxicity study
In both acute and sub-acute toxicity studies of DRAE, female
mice were used as recommended by OECD 420 as females were
generally slightly more sensitive [22].
There was no dose-related toxicity effect observed since the
mice appeared healthy with normal eyes, mucous membranes,
fur and skin condition. Mortality was absent in both treatment
and control groups. All the treated mice did not show any sig-
niﬁcant weight loss throughout the experiment, suggesting that
the animals were free from wasting syndrome. According to
Peterson et al., loss of body weight or wasting syndrome is a
characteristic sign observed in most animals in toxicity studies
[35]. The weight loss usually manifests within a few days after
exposure and results in a substantial reduction of the adipose
and muscle tissue observed at autopsy [36]. However, the mice
treated with the highest dose of DRAE (5000 mg/kg)
experienced a signiﬁcant weight gain compared to the control.
It may be one of the indicators of general systemic toxicity
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hormonal and homeostatic mechanisms could have occurred that
leads to weight gain [37]. The body weight gain can be explained
by an increase in percentage of kidney to body weight ratio in
the mice treated with 5000 mg/kg. Nevertheless, the
enlargement of kidney is not considered attributable to the
treatment because the histological examination illustrates
normal architecture of kidney. Enlargement of kidney might
be the result of a physiological response to exposure to a very
high dose of DRAE, which is not part of the normal diet [38].
The enlargement is most likely adaptive and not
toxicologically relevant. In addition, according to OECD,
histopathological examination is considered to be a more
sensitive marker of organ toxicity than organ weight [23].
According to the OECD 420 guideline, acute toxicity study
provides information on the hazardous properties and allows the
substance to be classiﬁed according to the Globally Harmonized
System of classiﬁcation and labeling of chemicals. Since the
LD50 cut-off value of DRAE can be considered to exceed
5000 mg/kg, no hazard classiﬁcation or labeling is required. It is
suggested that DRAE is considered safe or practically non-toxic.
4.2. Sub-acute toxicity study
Oral toxicity evaluation by using a 28-day toxicity test is an
accustomed practice in a sub-acute study. There was no dose-
related toxicity effect observed in the all treatment groups
(250, 500 and 1000 mg/kg of DRAE) since the mice appeared
healthy with normal eyes, mucous membranes, fur and skin
condition. Mortality was not detected in both control and treat-
ment groups.
There was no weight loss of more than 20% in all the DRAE-
treated mice, rejecting the hypothesis that the mice might be
experiencing wasting syndrome, a sign of toxicity as mentioned
by Peterson et al. [35]. Moreover, all the treatment groups were
having normal percentage of organ to body weight ratio of
kidneys, liver, spleen, heart, lungs and stomach, indicating that
treatment of DRAE didn't affect the development of these
organs [39].
There was no signiﬁcant difference in both urea and creati-
nine serum level indicating absence of toxicity to the kidney
caused by DRAE. Reinforcing these data, the histopathological
ﬁndings of kidney revealed no abnormality of the organ. Based
on the both biochemical analysis and histopathological exami-
nation, DRAE did not affect the renal function. Treatment with
all doses of DRAE also did not change the plasma level of liver
enzymes. Nevertheless, the liver of mice treated with 1000 mg/
kg of DRAE exhibited area of mild hemorrhage. It shows that
high dose of DRAE may cause some toxic effects to the liver but
not to the extent of altering the functions of the organ. It is
suggested that the no observable adverse effect level of DRAE
in this study is 500 mg/kg. From the no observable adverse
effect level, human equivalent dose is calculated by normalized
to body surface area. The safety dose of DRAE to be consumed
by human daily is 2.4 g.
DRAE possesses anti-breast cancer properties that are dose-
dependent. Based on the acute toxicity study, treatment with
625, 1250, 2500 and 5000 mg/kg of DRAE was not toxic to the
animals, indicating its safety when a large amount of this plant
extract is ingested. Based on the sub-acute toxicity study,
treatment of the highest dose of DRAE (1000 mg/kg) has mild
liver toxicity as indicated by mild focal hemorrhage.Conﬂict of interest statement
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